THE ARISING · Longevity & Healthspan
Pelacarsen Lowered Lp(a) but Did Not Reduce Major Cardiovascular Events
A large randomized trial found a substantial change in the blood marker, without evidence of fewer events on its main clinical measure.
A better blood-test result is not always the same as better health. The Lp(a)HORIZON trial illustrates that distinction. Pelacarsen substantially lowered lipoprotein(a), or Lp(a), but did not reduce the trial’s combined measure of major cardiovascular events.
The Novartis-funded study randomly assigned 8,350 people who had cardiovascular disease and elevated Lp(a) to pelacarsen or placebo. The efficacy analysis included 8,322 participants, and median follow-up was 4.7 years. At 12 months, median Lp(a) was about 64 nmol/L in the pelacarsen group and 233 nmol/L in the placebo group.
The primary outcome, which combined cardiovascular death, nonfatal heart attack, nonfatal stroke, and urgent coronary revascularization, occurred in 12.3% of the pelacarsen group and 12.1% of the placebo group. The estimated hazard ratio was 1.02, with a 95% confidence interval from 0.90 to 1.15. The study also did not show a benefit on that composite among participants with higher starting Lp(a), at least 90 mg/dL.
The result concerns this treatment regimen, this study population, and this combined outcome. It does not establish that the groups had identical rates of each event separately. It does not establish that Lp(a) is harmless or answer whether another treatment, a different clinical population, or a longer follow-up would produce a different result. For a treatment meant to prevent illness, the key question remains whether changing the marker translates into better health, not just whether the number changes.
Original New England Journal of Medicine study by Cho and colleagues